Publicacions en col·laboració amb investigadors/es de Complejo Hospitalario Universitario de Albacete (18)

2024

  1. Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism

    Frontiers in Endocrinology, Vol. 15

  2. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

  5. Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register

    Endocrine, Vol. 84, Núm. 2, pp. 683-693

  6. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

  7. Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas

    Journal of Hypertension, Vol. 42, Núm. 2, pp. 252-259

  8. Robotic and Laparoscopic Adrenalectomy for Pheochromocytoma: An International Multicenter Study

    European Urology Focus

2023

  1. An Integrated CT and MRI Imaging Model to Differentiate between Adrenal Adenomas and Pheochromocytomas

    Cancers, Vol. 15, Núm. 14

  2. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications on cardiometabolic profile and on surgical outcomes

    Endocrine Connections, Vol. 12, Núm. 9

  3. Differences in intraoperative and surgical outcomes between normotensive pheochromocytomas and sympathetic paragangliomas (PPGLs) and hypertensive PPGLs: results from the PHEO-RISK STUDY

    Journal of Endocrinological Investigation, Vol. 46, Núm. 4, pp. 805-814

  4. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

    Frontiers in Endocrinology, Vol. 14

  5. Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

    Neuroendocrinology, Vol. 113, Núm. 6, pp. 657-666

  6. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas

    Frontiers in Endocrinology, Vol. 14

  7. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

    Journal of Endocrinological Investigation, Vol. 46, Núm. 11, pp. 2343-2352

2022

  1. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas

    Endocrine-related cancer, Vol. 29, Núm. 12, pp. 645-655

  2. Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours

    Scientific reports, Vol. 12, Núm. 1, pp. 2671

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819